Do analysts rate LPCN or MBIO?

Lipocine currently has a consensus price target of $15.00, suggesting a potential upside of 527.62%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LPCN or MBIO more profitable?

Mustang Bio has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Mustang Bio's return on equity of -35.38% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -571.18% -66.70% -59.39% Mustang Bio N/A -35.38% -16.36%

Do analysts recommend CELU or MBIO?

Celularity presently has a consensus target price of $6.00, indicating a potential upside of 868.21%. Given Celularity's stronger consensus rating and higher probable upside, equities research analysts plainly believe Celularity is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELU or MBIO more profitable?

Mustang Bio has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Mustang Bio N/A -35.38% -16.36%

Do analysts rate MBIO or CLRB?

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 291.46%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings & valuation, MBIO or CLRB?

Mustang Bio is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mustang Bio N/A N/A -$1.92M -$0.48 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is MBIO or CLRB more profitable?

Mustang Bio's return on equity of -35.38% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -35.38% -16.36% Cellectar Biosciences N/A -349.24% -153.18%

Do analysts prefer PASG or MBIO?

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 183.12%. Given Passage Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Passage Bio is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, PASG or MBIO?

Mustang Bio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Mustang Bio N/A N/A -$1.92M -$0.48 N/A

Is PASG or MBIO more profitable?

Mustang Bio's return on equity of -35.38% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Mustang Bio N/A -35.38% -16.36%

Do analysts recommend LNAI or MBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LNAI or MBIO more profitable?

Mustang Bio's return on equity of -35.38% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Mustang Bio N/A -35.38% -16.36%

Mustang Bio (MBIO) Competitors

$0.70 0.00 (0.00%)

As of 07/2/2026 03:59 PM Eastern

Compare

MBIO vs. LPCN, CELU, CLRB, PASG, and LNAI

Should you buy Mustang Bio stock or one of its competitors? MarketBeat compares Mustang Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mustang Bio include Lipocine (LPCN), Celularity (CELU), Cellectar Biosciences (CLRB), Passage Bio (PASG), and Lunai Bioworks (LNAI). These companies are all part of the "pharmaceutical products" industry.

How does Mustang Bio compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Mustang Bio has lower revenue, but higher earnings than Lipocine. Mustang Bio is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.95	-$9.63M	-$1.88	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

Mustang Bio has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Mustang Bio's return on equity of -35.38% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
Mustang Bio	N/A	-35.38%	-16.36%

Lipocine has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 9.9% of Mustang Bio shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Lipocine's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Company	Overall Sentiment
Lipocine	Neutral
Mustang Bio	Neutral

Lipocine currently has a consensus price target of $15.00, suggesting a potential upside of 527.62%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mustang Bio beats Lipocine on 7 of the 13 factors compared between the two stocks.

How does Mustang Bio compare to Celularity?

Celularity (NASDAQ:CELU) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

In the previous week, Celularity's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Company	Overall Sentiment
Celularity	Neutral
Mustang Bio	Neutral

Celularity has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market.

Mustang Bio has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Mustang Bio	N/A	-35.38%	-16.36%

Mustang Bio has lower revenue, but higher earnings than Celularity. Mustang Bio is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.68	-$91.72M	-$3.33	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

19.0% of Celularity shares are owned by institutional investors. Comparatively, 9.9% of Mustang Bio shares are owned by institutional investors. 17.3% of Celularity shares are owned by company insiders. Comparatively, 4.0% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Celularity presently has a consensus target price of $6.00, indicating a potential upside of 868.21%. Given Celularity's stronger consensus rating and higher probable upside, equities research analysts plainly believe Celularity is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Celularity beats Mustang Bio on 8 of the 13 factors compared between the two stocks.

How does Mustang Bio compare to Cellectar Biosciences?

Mustang Bio (NASDAQ:MBIO) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

In the previous week, Cellectar Biosciences had 2 more articles in the media than Mustang Bio. MarketBeat recorded 2 mentions for Cellectar Biosciences and 0 mentions for Mustang Bio. Cellectar Biosciences' average media sentiment score of 0.47 beat Mustang Bio's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Mustang Bio	Neutral
Cellectar Biosciences	Neutral

Mustang Bio is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Mustang Bio's return on equity of -35.38% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-35.38%	-16.36%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Mustang Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 291.46%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

9.9% of Mustang Bio shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 4.0% of Mustang Bio shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cellectar Biosciences beats Mustang Bio on 7 of the 13 factors compared between the two stocks.

How does Mustang Bio compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 9.9% of Mustang Bio shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mustang Bio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 183.12%. Given Passage Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Passage Bio is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mustang Bio's return on equity of -35.38% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Mustang Bio	N/A	-35.38%	-16.36%

Passage Bio has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market.

In the previous week, Passage Bio had 3 more articles in the media than Mustang Bio. MarketBeat recorded 3 mentions for Passage Bio and 0 mentions for Mustang Bio. Passage Bio's average media sentiment score of 1.51 beat Mustang Bio's score of 0.00 indicating that Passage Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Passage Bio	Very Positive
Mustang Bio	Neutral

Summary

Passage Bio beats Mustang Bio on 8 of the 13 factors compared between the two stocks.

How does Mustang Bio compare to Lunai Bioworks?

Lunai Bioworks (NASDAQ:LNAI) and Mustang Bio (NASDAQ:MBIO) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Mustang Bio has lower revenue, but higher earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	$20.94K	692.81	-$178.01M	-$0.40	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lunai Bioworks had 1 more articles in the media than Mustang Bio. MarketBeat recorded 1 mentions for Lunai Bioworks and 0 mentions for Mustang Bio. Lunai Bioworks' average media sentiment score of 0.67 beat Mustang Bio's score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Positive
Mustang Bio	Neutral

Lunai Bioworks has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

Mustang Bio's return on equity of -35.38% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Mustang Bio	N/A	-35.38%	-16.36%

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 9.9% of Mustang Bio shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Comparatively, 4.0% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Mustang Bio beats Lunai Bioworks on 6 of the 11 factors compared between the two stocks.

Get Mustang Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBIO vs. The Competition

Export

Metric	Mustang Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.33M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.46	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.54	8.66	10.96	6.46
Net Income	-$1.92M	$23.81M	$3.57B	$337.01M
7 Day Performance	-0.04%	3.39%	2.12%	1.69%
1 Month Performance	4.93%	10.81%	5.25%	3.81%
1 Year Performance	-42.14%	62.61%	33.29%	23.90%

Mustang Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBIO Mustang Bio	0.4388 of 5 stars	$0.70 flat	N/A	-42.1%	$5.33M	N/A	N/A	100
LPCN Lipocine	3.2942 of 5 stars	$2.53 +10.5%	$15.00 +492.9%	-26.9%	$20.85M	$1.98M	N/A	10
CELU Celularity	1.4098 of 5 stars	$0.70 -7.7%	$6.00 +757.4%	-69.8%	$20.26M	$26.55M	N/A	220	Gap Down
CLRB Cellectar Biosciences	4.3677 of 5 stars	$2.50 -2.7%	$11.00 +340.0%	-41.7%	$19.98M	N/A	N/A	10	News Coverage
PASG Passage Bio	4.7051 of 5 stars	$6.12 +7.0%	$13.25 +116.5%	-49.2%	$19.63M	N/A	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBIO) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mustang Bio (MBIO) Competitors

MBIO vs. LPCN, CELU, CLRB, PASG, and LNAI

How does Mustang Bio compare to Lipocine?

Summary

How does Mustang Bio compare to Celularity?

Summary

How does Mustang Bio compare to Cellectar Biosciences?

Summary

How does Mustang Bio compare to Passage Bio?

Summary

How does Mustang Bio compare to Lunai Bioworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO vs. The Competition

Mustang Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mustang Bio (MBIO) Competitors

MBIO vs. LPCN, CELU, CLRB, PASG, and LNAI

How does Mustang Bio compare to Lipocine?

Which has better valuation and earnings, LPCN or MBIO?

Is LPCN or MBIO more profitable?

Which has more volatility and risk, LPCN or MBIO?

Do insiders & institutionals hold more shares of LPCN or MBIO?

Does the media favor LPCN or MBIO?

Do analysts rate LPCN or MBIO?

Summary

How does Mustang Bio compare to Celularity?

Does the media favor CELU or MBIO?

Which has more risk & volatility, CELU or MBIO?

Is CELU or MBIO more profitable?

Which has higher valuation & earnings, CELU or MBIO?

Do insiders and institutionals have more ownership in CELU or MBIO?

Do analysts recommend CELU or MBIO?

Summary

How does Mustang Bio compare to Cellectar Biosciences?

Does the media refer more to MBIO or CLRB?

Which has better earnings & valuation, MBIO or CLRB?

Is MBIO or CLRB more profitable?

Which has more volatility and risk, MBIO or CLRB?

Do analysts rate MBIO or CLRB?

Do insiders & institutionals believe in MBIO or CLRB?

Summary

How does Mustang Bio compare to Passage Bio?

Do insiders & institutionals believe in PASG or MBIO?

Which has preferable earnings & valuation, PASG or MBIO?

Do analysts prefer PASG or MBIO?

Is PASG or MBIO more profitable?

Which has more risk & volatility, PASG or MBIO?

Does the media favor PASG or MBIO?

Summary

How does Mustang Bio compare to Lunai Bioworks?

Which has higher valuation & earnings, LNAI or MBIO?

Do analysts recommend LNAI or MBIO?

Does the media favor LNAI or MBIO?

Which has more risk and volatility, LNAI or MBIO?

Is LNAI or MBIO more profitable?

Do insiders & institutionals believe in LNAI or MBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO vs. The Competition

Mustang Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools